Eli Lilly and Company (NYSE:LLY)’s shares have become one of the most valuable in the sector due to its strong presence in the weight loss drug industry.

Eli Lilly pauses UK Mounjaro shipments until September 1, aligning with a projected 170% price increase, while implementing safeguards against stockpiling. The US government pressures pharmaceutical ...

Eli Lilly announced this week that its new weight-loss pill, orforglipron, cleared its latest Phase 3 trial, bringing it closer to potential Food and Drug Administration (FDA) approval. Compared with ...

Denmark cuts 2025 growth forecast as Novo Nordisk slowdown and US tariffs raise fears of over-reliance on pharma.

Eli Lilly partners with JD Health to expand in China’s obesity drug market, leveraging digital platforms for growth.

The company behind popular weight loss drug Mounjaro has offered a discounted deal to UK suppliers which is expected to limit ...

Serena Williams, the tennis legend turned businesswoman, has taken on a new role as global ambassador for Ro, the telehealth company best known for its weight loss treatments, including the ...

Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term on LLY stock.

Eli Lilly's orforglipron outshines Novo Nordisk's oral semaglutide with efficacy & scalability, promising growth in the ...

Eli Lilly has temporarily halted UK shipments of its weight-loss drug Mounjaro ahead of a significant price increase set for ...

Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the ...

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...